Loading...
Loading...
Brean Murray Carret maintains its Buy rating on DexCom
DXCM and raises its price target $1 to $13.50 a share on on several updates of interest by the company.
Brean Murray Carret says, "Management did firmly communicate its intent to be cash flow positive during 2013 and perhaps as early as late 2012 (our model remains more conservative). The company also confirmed the completion of their Gen4 sensor pivotal trial and will file near term, which we think is slightly ahead of consensus expectations. The small acquisition of a universal data management system vendor, SweetSpot, should also be well received."
DXCM closed at $11.19 a share on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in